OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - ASTRAZENECA | Market Closed - Deutsche Boerse AG 20:45:33 23/05/2024 BST | ||
| 5.69 EUR | +1.25% |
|
| Current month | +6.75% | ||
| 1 month | +26.16% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 5.69 | +1.25% |
| 22/05/24 | 5.62 | -3.27% |
| 21/05/24 | 5.81 | +8.40% |
| 20/05/24 | 5.36 | -1.29% |
| 17/05/24 | 5.43 | -0.37% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 08:45 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SD8WD0 |
| ISIN | DE000SD8WD02 |
| Date issued | 04/03/2021 |
| Strike | 7,453 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.11 € |
|---|---|
| Lowest since issue | 0.37 € |
| Spread | 0.08 € |
| Spread % | 1.39% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.7
USD
Average target price
169.7
USD
Spread / Average Target
+7.62%
- Stock Market
- Certificates
- Certificat
